PGEN
Precigen Inc
About PGEN
Precigen, Inc. (Precigen) is a synthetic biology company that focuses on its discovery and clinical-stage activities to advance gene and cellular therapies to target immuno-oncology, autoimmune disorders, and infectious diseases. Its therapeutic platforms, including UltraCAR-T, AdenoVerse immunotherapy, and ActoBiotics, are designed to precisely control the level and physiological location of gene expression and modify biological molecules to control the function and output of living cells to treat underlying disease conditions. The Company’s lead clinical programs, including: PRGN-3005, PRGN-3006, and PRGN-3007, which are built on its UltraCAR-T platform; PRGN-2009 and PRGN-2012, which are based on its AdenoVerse immunotherapy platform; and AG019, which is built on its ActoBiotics platform. The Company also completed a Phase I study of INXN-4001, a non-viral triple-effector plasmid DNA, which is built on its UltraVector platform. It also has a robust pipeline of preclinical programs.
Buy US stocks in Australia starting with PGEN. Open an account and start investing today!
$254.72M
-
0.00%
0
$1.03
$0.90
$0.00
$2.90
$0.90
PGEN FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in PGEN
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.